Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced that its management team will participate in two upcoming investor conferences in March 2026. Seth Lederman, M.D., president and chief executive officer, will deliver a company presentation at the TD Cowen 46th Annual Healthcare Conference on Wednesday, March 4, 2026, from 11:10 a.m. to 11:40 a.m. ET at the Boston Marriott Copley Place in Boston. In addition, management will participate in one-on-one meetings at the Barclays 28th Annual Healthcare Conference, scheduled for March 10-12, 2026, at the Loews Miami South Beach Hotel in Miami Beach.
The company’s presence at these premier investor events underscores its commitment to advancing its pipeline in central nervous system (CNS) and immunology treatments. Tonix is a fully-integrated, commercial-stage biotechnology company focused on areas of high unmet medical need. Its recently approved flagship medicine, TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), represents the first new treatment for fibromyalgia in more than 15 years. The company’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace SymTouch and Tosymra.
Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. Additionally, the company’s CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. In immunology, Tonix is advancing a pipeline that includes monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
These investor conferences provide a platform for Tonix to communicate its strategic vision and progress to the investment community. The TD Cowen conference, in particular, offers a focused opportunity for the CEO to present the company’s latest developments and future plans. The one-on-one meetings at Barclays allow for deeper discussions with potential investors and analysts.
Tonix’s participation comes at a pivotal time as the company seeks to leverage its commercial infrastructure and pipeline to drive growth. The recent approval of TONMYA marks a significant milestone, and the company is actively exploring additional indications for the drug. The conferences also allow Tonix to highlight its immunology programs, which target high-value indications such as Lyme disease prevention and transplant rejection.
For more information about Tonix Pharmaceuticals, visit the company’s newsroom at https://ibn.fm/TNXP. To view the full press release, visit https://ibn.fm/TToz2.
